Switching the targeting pathways of a therapeutic antibody by nanodesign

Sanjib Bhattacharyya, Raman Deep Singh, Richard Pagano, J. David Robertson, Resham Bhattacharya, Priyabrata Mukherjee

Research output: Contribution to journalArticle

34 Scopus citations


On the right path: The mechanisms of endocytosis of cetuximab (C225) and its nanoconjugates have been elucidated in a pancreatic cancer cell line. By using gold nanoparticles as a scaffold, it is possible to switch the pathway for endocytosis from a Dyn-2-dependent caveolar mechanism to Cdc42-dependent pinocytosis/phagocytosis. Tailoring endocytotic mechanisms may enable specific intracellular pathways to be targeted.

Original languageEnglish (US)
Pages (from-to)1563-1567
Number of pages5
JournalAngewandte Chemie - International Edition
Issue number7
StatePublished - Feb 13 2012



  • drug delivery
  • endocytosis
  • gold
  • lipid microdomains
  • nanoparticles

ASJC Scopus subject areas

  • Catalysis
  • Chemistry(all)

Cite this

Bhattacharyya, S., Singh, R. D., Pagano, R., Robertson, J. D., Bhattacharya, R., & Mukherjee, P. (2012). Switching the targeting pathways of a therapeutic antibody by nanodesign. Angewandte Chemie - International Edition, 51(7), 1563-1567. https://doi.org/10.1002/anie.201105432